Precision radiation offers new hope for recurrent prostate cancer
NCT ID NCT03312972
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a focused radiation technique called HDR brachytherapy for men whose prostate cancer has come back after earlier radiation treatment. The radiation is placed directly into the cancerous area and removed after a short time, aiming to spare healthy tissue. The trial will enroll 50 participants to check how safe and effective this approach is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HDR brachytherapy (high-dose-rate radiation implant)
- What this could lead to
- If successful, this could offer a targeted, less invasive treatment option for men whose prostate cancer has come back after initial radiation therapy.
- What could go wrong
- This is an early-phase trial with only 50 participants, so results may not apply to everyone. There is a risk of side effects from radiation, and the treatment may not control the cancer long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY RECURRENT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Loyola University Medical Center
Maywood, Illinois, 60153, United States
-
University of Virginia School of Medicine
Charlottesville, Virginia, 22908, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.